Ask about this productRelated genes to: MAPK3 Blocking Peptide
- Gene:
- MAPK3 NIH gene
- Name:
- mitogen-activated protein kinase 3
- Previous symbol:
- PRKM3
- Synonyms:
- ERK1, p44mapk, p44erk1
- Chromosome:
- 16p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1993-11-05
- Date modifiied:
- 2015-09-03
Related products to: MAPK3 Blocking Peptide
Related articles to: MAPK3 Blocking Peptide
- Malus micromalus Makino, a fruit crop with a millennium-long cultivation heritage in China, has hitherto received limited systematic investigation regarding its bioactive principles and the mechanistic underpinnings of its glucose-modulating effects. Sixteen compounds were isolated and structurally identified from the fruit. The bioactive components and action modes were systematically explored via network pharmacology, in vitro bioassays, enzyme kinetics, molecular simulation, and in vivo validation. ESR1 and MAPK3 were predicted as potential hub targets involved in insulin resistance and oxidative stress regulation. Oleanolic acid, ursolic acid, and hyperoside exhibited dual functional activities, with potent α-glucosidase inhibitory effects (IC = 0.037, 0.038, and 0.047 mM, respectively) stronger than acarbose in this yeast-derived enzyme assay system, plus remarkable DPPH, and ABTS radical scavenging capacities. Enzyme kinetic analysis demonstrated a noncompetitive inhibition mode, with unchanged K value, and dose-dependently decreased V. Molecular docking indicated that OA and UA had high binding affinities with ESR1 and MAPK3. Notably, 100-ns molecular dynamics simulation suggested that OA could form sustained hydrogen bonds with ESR1 and maintain the structural stability of the receptor-ligand complex. Within the in vivo setting, OA treatment at 25 and 50 mg/kg engendered dose-dependent improvements in systemic glucose handling, peripheral insulin sensitivity, and circulating lipid profiles among HFD-induced obese animals. Collectively, this study clarifies the bioactive constituents and metabolic regulatory effects of M. micromalus Makino, and provides scientific evidence for its development as a functional food ingredient for glycemic management. PRACTICAL APPLICATIONS: The present findings offer direct translational value for the functional food sector. The potent α-glucosidase inhibitory activity of oleanolic acid (OA, IC = 0.037 mM)-surpassing acarbose by approximately sevenfold-positions M. micromalus fruit extracts as promising candidates for glycemic-management food ingredients. Given its noncompetitive inhibition kinetics, OA retains efficacy irrespective of carbohydrate load, a critical advantage for incorporation into staple foods with variable starch content. From a formulation standpoint, the ethyl acetate fraction enriched in triterpenoids and flavonoids could be developed as standardized extracts for functional beverages, bakery products, or nutraceutical capsules. The established industrial processing of M. micromalus into fruit wine and preserves further supports scalable valorization. However, the poor aqueous solubility of pentacyclic triterpenoids necessitates future work on delivery systems (e.g., nano-emulsions or liposomal encapsulation) to enhance bioavailability and thermal stability during food processing. In addition, the dual antioxidant-hypoglycemic profile of these constituents suggests potential as multifunctional natural preservatives that simultaneously extend shelf life and confer metabolic health benefits. Subsequent studies should evaluate the sensory impact, storage stability, and consumer acceptability of M. micromalus-fortified food prototypes. - Source: PubMed
Hao BaocongLiang HaiPeng LijuanZhu ZihanZhang YuLi HongxiaGuo TiantianLiu Qingchao - Thyroid cancer (THCA) has recently become one of the most common endocrine malignancies worldwide. Dihydroartemisinin (DHA) exhibits well-documented antitumor activity, but its therapeutic potential in THCA remains largely unclear. - Source: PubMed
Xie XiaozhangMiao JianhangDeng JianweiZheng BingxingZhong LinkunNing LiqingSun Jingjing - Ginseng dripping pills (GDPs), a traditional Chinese patent medicine, are extensively used for cardiovascular diseases (CVDs), but their active components and underlying mechanisms remain unclear. This study aimed to identify the chemical constituents of GDP and to explore their potential mechanisms in treating myocardial infarction (MI) and atherosclerosis (AS). Chemical profiling was performed using ultra-high-performance liquid chromatography coupled with Q-Exactive hybrid quadrupole-Orbitrap mass spectrometry (UHPLC-Q-Orbitrap MS) and the Global Natural Products Social Molecular Networking (GNPS), leading to the identification of 113 compounds, and 13 blood-absorbed components were identified, with ginsenosides identified as the predominant bioactive constituents. Network pharmacology was then used to predict the key therapeutic targets and associated signaling pathways, and a comprehensive "GDP-component-target-pathway" interaction network was constructed. 18 targets were identified as core targets of GDP in treating CVD. The main pathways involved included PI3K-Akt, RAS, cAMP, Rap1, and calcium signaling. Molecular docking showed that 13 blood-absorbed components of GDP, including ginsenoside Ro, ginsenoside Rs1 and ginsenoside Ra3, had strong binding affinities with MAPK3, MMP9, and PTGS2. These findings suggest that GDP may exert cardioprotective effects through a multicomponent, multitarget, and multipathway mode of action, providing a scientific basis for its clinical application in CVD treatment. - Source: PubMed
Publication date: 2026/09/28
Xu MinglinMao JunyiWang XiangnanJiang JinpingOcholi Simon SaniWang ChaoyangWang YueYu HonghaiHan Lifeng - Gegen Qinlian Decoction (GQD) has shown preclinical antidepressant-like effects, but the disease-relevant signalling architecture of its putative targets remains unclear. - Source: PubMed
Publication date: 2026/09/23
Gao ZixiangLi XiangZhou XianqiZhou ZixuanLi Zining - Xiaoyaosan (XYS) has significant anti-inflammatory effects and is widely used for treating depression. However, the multitarget mechanism of XYS in the treatment of bipolar disorder (BD) remains unexplored. In this study, network pharmacology, molecular docking, and experimental validation were integrated to elucidate the mechanisms of XYS and its therapeutic efficacy in BD. - Source: PubMed
Chen ManDing NanaQiu XingminLi LanGuo YaliWang RongyanqiMo XiaoweiZou TanYu ShangzhenLi XiaojuanChen Jiaxu